Brief: United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction In Risk Of Clinical Worsening In Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
02/03/2026 14:10
March 2 (Reuters) - United Therapeutics Corp UTHR.O: UNITED THERAPEUTICS CORPORATION ANNOUNCES RALINEPAG ACHIEVED 55% REDUCTION IN RISK OF CLINICAL WORSENING IN PIVOTAL PULMONARY ARTERIAL HYPERTENSION STUDY, DELIVERING EXCEPTIONAL, HIGHLY STATISTICALLY SIGNIFICANT EFFICACY UNITED THERAPEUTICS CORP - NDA FOR RALINEPAG TO BE SUBMITTED TO FDA BY H2 2026 UNITED THERAPEUTICS CORP - RALINEPAG TREATMENT WELL-TOLERATED WITH CONSISTENT SAFETY PROFILE UNITED THERAPEUTICS CORP - PHASE 3 STUDY OF RALINEPAG MEETS PRIMARY ENDPOINT, 47% CLINICAL IMPROVEMENT Source text: ID:nBw128cCZa Further company coverage: UTHR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug